Outcomes of different revascularization strategies among patients presenting with acute coronary syndromes without ST

Eilon Ram1, Leonid Sternik1, Robert Klempfner2

  • 1Department of Cardiac Surgery, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel; Department of Cardiology, Leviev Cardiothoracic and Vascular Center, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.

Insights

Coronary artery bypass grafting (CABG) shows better long-term survival than percutaneous coronary intervention (PCI) for non-ST-segment myocardial infarction (NSTEMI) or unstable angina (UA). This benefit was observed exclusively in male patients, highlighting sex-specific outcomes in cardiac revascularization.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Non-ST-segment myocardial infarction (NSTEMI) and unstable angina (UA) are acute coronary syndromes requiring revascularization.
  • Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are primary revascularization strategies.
  • Real-world data comparing long-term outcomes of CABG versus PCI in NSTEMI/UA patients is crucial.

Purpose of the Study:

  • To compare short- and long-term outcomes of NSTEMI/UA patients treated with CABG versus PCI.
  • To identify predictors for CABG referral in a real-world setting.
  • To analyze sex-specific differences in outcomes following revascularization.

Main Methods:

  • Observational study of 5112 NSTEMI/UA patients from the Acute Coronary Syndrome Israeli Survey (2000-2016).
  • Propensity score-matching analysis (1:1) comparing early outcomes and all-cause mortality between CABG and PCI groups.
  • Multivariable analysis to identify independent predictors of mortality and referral patterns.

Main Results:

  • CABG referral was associated with 3-vessel coronary artery disease (CAD), absence of on-site cardiac surgery, no prior PCI, and no prior myocardial infarction.
  • The 10-year mortality risk was significantly lower for CABG (20.4%) compared to PCI (28.4%) (P=0.006).
  • CABG referral independently reduced 10-year mortality risk by 65% (P < 0.001), an advantage observed only in male patients.

Conclusions:

  • CABG offers superior long-term outcomes compared to PCI in patients with NSTEMI or UA in a real-world setting.
  • The survival benefit of CABG over PCI is sex-specific, predominantly benefiting male patients.
  • These findings emphasize the importance of considering patient sex in revascularization strategy selection.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
191
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
675
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
319
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
179
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
199
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
205